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Abstract 
Background: Diagnosis and monitoring of localized prostate cancer requires discovery and 
validation of non-invasive biomarkers. NMR-based metabolomics of seminal plasma reportedly 
improves diagnostic accuracy, but requires validation in a high-risk clinical cohort. 
Methods: Seminal plasma samples of 151 men being investigated for prostate cancer were 
analysed with 1H-NMR spectroscopy. After adjustment for buffer (Add-to-Subtract) and 
endogenous enzyme influence on metabolites, metabolite profiling was performed with 
multivariate statistical analysis (principal components analysis, partial least squares) and targeted 
quantitation.  
Results: Seminal plasma metabolites best predicted low- and intermediate-risk prostate cancer 
with differences observed between these groups and benign samples. Lipids/lipoproteins 
dominated spectra of high grade samples with less metabolite contributions. Overall prostate 
cancer prediction using previously described metabolites was not validated.  
Conclusion: Metabolomics of seminal plasma in vitro may assist urologists with diagnosis and 
monitoring of either low or intermediate grade prostate cancer. Less clinical benefit may be 
observed for high-risk patients. Further investigation in active surveillance cohorts, and/or in 
combination with in vivo magnetic resonance spectroscopic imaging may further optimize 
localized prostate cancer outcomes. 
 
Keywords: biomarker, metabolomics, Nuclear Magnetic Resonance (NMR),  prostate cancer, 
seminal fluid 
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Abbreviations: 
CaP  prostate cancer 
csCaP  clinically significant prostate cancer 
HBSS   Hanks Balanced Salt Solution 
MRSI  magnetic resonance spectroscopic imaging 
MVSA  multivariate statistical analysis 
NMR  nuclear magnetic resonance 
PAP  prostatic acid phosphatase 
PBS  phosphate buffered saline 
PC  principal component 
PCA  principal components analysis 
PCA3  prostate cancer antigen 3 
PLS  partial least squares 
PSA  prostate specific antigen 
RP   radical prostatectomy 
SP  seminal plasma 
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Introduction 
Accurate prostate cancer (CaP) diagnosis to prolong life with minimal morbidity is a daily 
challenge for urologists. While early treatment of localized clinically significant CaP (csCaP) 
with curative intent reduces mortality and metastases1, harms associated with over detection and 
treatment of indolent CaP driven by injudicious use of serum prostate specific antigen (PSA) and 
prostate biopsy have reduced overall CaP detection2. Limitations of serum PSA have driven 
advancements in multiparametric magnetic resonance imaging and biomarkers in serum (e.g. 
Prostate Health Index) and urine (prostate cancer antigen 3 (PCA3), TMPRSS2:ERG fusion 
gene)3-6. However, due to cost-effectiveness concerns, these are used as adjunctive tests rather 
than as standalone detection tests despite their improved diagnostic accuracy5,6.  
Prostatic fluid, produced as seminal plasma (SP) after physiological prostatic smooth muscle 
contraction, contains the clinical biomarkers PSA and prostatic acid phosphatase (PAP)7,8. 
Malignant prostatic cells in ejaculates of men with CaP have been shown to express genes 
(PCA3, Hepsin) and microRNAs that improve detection compared to serum PSA9-11. 
Metabolomics is a modern biomarker approach that quantifies small metabolites, most 
commonly using nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry12,13. 
NMR-based metabolomics is highly sensitive and reproducible with affordable sample-to-sample 
costs12. SP metabolite profiles improve PSA-based diagnosis14,15, but require clinical validation. 
This study investigates the feasibility of SP analysis using NMR-based metabolomics for the 
prediction of csCaP in a high-risk clinical cohort and compares metabolite profile CaP diagnosis 
against prostate biopsy and radical prostatectomy (RP) histology. 
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Subjects and Methods 
Ethical approval was obtained from the University of Queensland Medical Research Ethics 
Committee (Project no. 2006000262) and the Royal Brisbane and Women’s Hospital Human 
Research Ethics Committee (HREC/09/QRBW/320, HREC/09/QRBW/305 and 1995/088B).  
Patients and Clinical data 
Male patients (n=154) attending either the Royal Brisbane and Women’s Hospital Urology 
outpatient department or local private consulting rooms for investigation of elevated PSA and/or 
abnormal digital rectal examination between January 2007 and February 2013 were enrolled in 
this prospective cohort study. Following informed consent, patients provided ejaculate specimens 
on site or at home prior to or at least one month after prostate biopsy, prior to commencement of 
any treatment.  No specifications to time of day, relation to voiding, urethral meatus sterilization 
or other parameters were provided to patients to simplify the sample collection process. Patients 
denied surgical treatment for BPH and subsequent retrograde ejaculation prohibiting sample 
collection. 
Patient data collected included age, serum PSA and detailed prostate biopsy and radical 
prostatectomy histology records. Biopsy and RP specimens were reported by uropathologists 
according to the 2005 International Society of Urological Pathology classification16. Patients 
were monitored for biopsy progression, such as CaP detection following initial false negative 
biopsy or upgraded Gleason score with further biopsy or RP (n=60).  
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Risk stratification (low, intermediate, high risk) was performed according to the D’Amico 
criteria recommended in the American Urological Association Guidelines17 and used to 
determine csCaP presence (intermediate, high risk requiring treatment; Table 1). Given 
established disparity between biopsy and RP histopathology, risk classification accuracy was 
optimised using whichever histopathology best described tumour characteristics.  
Specimen processing  
Ejaculate specimens were deposited directly into sterile micro-urine jars containing 20 ml Hanks 
Balanced Salt Solution (HBSS) (Gibco) for the first 117 patients used initially for cytology and 
RNA analyses, which was thereafter replaced by Phosphate Buffered Saline (PBS) (in-house 
preparation) because glucose in HBSS interfered with preliminary metabolomics analysis (Figure 
2a-c). All specimens were provided to the laboratory without cooling as soon as logistically 
possible by the patients and were processed in the laboratory within 2 h of production. 
Specimens were combined with 20 ml HBSS or PBS, layered over 10 ml isotonic Percoll (GE 
Healthcare-Pharmacia) and centrifuged at 974×g for 30-60 min at 4°C. Isolated supernatants, 
herein referred to as SP, were snap-frozen on dry ice in 1 ml aliquots and stored at –80°C.  
Sample preparation 
SP samples were thawed on wet ice and distributed in 100 µl aliquots. 80 µl of PBS solution 
were added along with 20 µL D2O as lock substance that contained 4,4-dimethyl-4-silapentane-
1-sulfonic acid as internal chemical shift standard and 1,1-difluoro-1-trimethylsilanyl 
methylphosphonic acid as internal pH indicator leading to final concentrations of 100 µM, 
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resulting in 200 µL total sample volume. Samples were transferred to sterile 3 mm NMR tubes 
(Bruker Biospin, Rheinstetten, Germany). 
NMR spectroscopy 
NMR spectra of SP samples were measured on a Bruker Avance 900 spectrometer operating at a 
1H frequency of 900.13 MHz (Bruker Biospin), equipped with a 5 mm self-shielded z-gradient 
triple resonance cryoprobe and SampleJet sample changer. One-dimensional (1D) NOESY 
spectra were acquired at 298 K with the “noesypr1d” pulse sequence, accumulating 200 
transients (following 8 dummy scans) at 32k data points with a spectral width of 14 ppm18. The 
transmitter frequency was set to the water resonance, which was suppressed by continuous wave 
irradiation during the NOESY mixing time of 0.1 s and relaxation delay of 3.0 s. 
Tuning/matching, shimming, and data acquisition were performed automatically with the ICON-
NMR interface for high-throughput automation. Samples were measured in one batch per sample 
collection buffer and ordered randomly within these batches.   
Spectral Processing 
NMR spectra were processed in TopSpin 3.2 (Bruker Biospin). The free induction decays were 
baseline corrected by a Gaussian function (0.1 ppm filter width) for post-acquisition water 
deconvolution19, followed by multiplication with an exponential window function (0.1 Hz line 
broadening), and Fourier transformation to 64k points. Subsequently, the spectra were manually 
phased, manually baseline corrected with a cubic spline curve, and referenced to DSS at 
0.0 ppm. For all further data manipulation, the spectra were truncated to δ=10.0–0.25 ppm, 
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exported into MATLAB 2015b (The Mathworks Inc., Natick, Massachusetts, United States), and 
scaled according to the Bruker NC_proc parameter. 
 “Add-to-Subtract” glucose exclusion  
Preliminary analysis revealed glucose at sometimes dominant levels in most samples (Figure 1). 
As HBSS contains 1 g/L D-glucose and ejaculate volumes were varied, the exogenous glucose 
concentration and its influence on subsequent multivariate statistical analysis (MVSA) was 
unpredictable. Thus, we used the “Add-to-Subtract” method20 to exclude glucose signals from 
the NMR spectra: First, we added 1 µl of 1 M D-glucose in PBS to each sample and repeated 
measurement with identical experimental parameters, leading to a total of 302 spectra for 151 
patients (151 original, 151 with additional glucose). Secondly, using Topspin’s multiple display, 
we determined the corresponding scaling factor between spectrum 2 and 1 for each sample that 
ensures elimination of the glucose signal upon subtraction. Then the exported spectra 1 and 2 for 
each sample were aligned using “icoshift”21 on the glucose peaks at 3.37–3.44 ppm and then 
along 10 equal segments. Finally, for each sample spectrum 2 was scaled with the scaling factor 
recorded in Topspin and subtracted from spectrum 1. The resulting difference spectra were 
stored in a separate matrix.  
Spectral alignment and data reduction  
The peaks of all difference spectra were aligned at full resolution using “icoshift”, initially on the 
lactate doublet at 1.32 ppm and subsequently on manually defined segments. No shifting 
artefacts were identified. Using an in-house MATLAB script, the aligned difference spectra were 
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data reduced to buckets of 0.01 ppm width over the range 10.0–5.08 and 4.52-0.25 ppm, 
excluding the water signal region. 
Multivariate statistical analysis  
Metabolite data (X) matrices containing original and difference (Add-to-Subtract) data were 
quantile normalized with the “affy” package22 in R version 3.2.223 and imported into SIMCA P+ 
12.0 (Umetrics, Umeå, Sweden) for MVSA together with clinical data variables (Y-matrix). 
X-matrices were Pareto-scaled before unsupervised Principal Components Analysis (PCA)24. To 
determine which metabolite signatures were associated with clinical data (cancer/risk status; Y-
matrix), supervised partial least squares (PLS) was performed24. Multivariate model quality was 
judged by the R2 (“goodness of fit”) and Q2 (“goodness of prediction”) figures of merit 
(Supplementary Table 1). PLS models were validated by 200-fold response permutation.   
Traditional statistical analysis, including the non-parametric Mann-Whitney U test, logistic 
regression and Receiver Operating Characteristic analysis were performed in MedCalc 12.7 for 
Windows (MedCalc Software; Ostend, Belgium). 
Targeted metabolite profiling 
SP metabolites were quantified using Chenomx NMR suite25 using DSS as internal concentration 
standard. Logistic regression on the SP metabolite concentrations was performed in MedCalc, 
similar to that described in15.  
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Results 
Clinical cohort demographics 
From 151 patients who provided SP samples, 80 were initially diagnosed with CaP and an 
additional 18 patients diagnosed during the follow-up period. Within these 98 patients, 82 met 
csCaP criteria. 60 patients underwent RP for localized CaP in which 59 were determined to be 
high risk per the D’Amico criteria, with 6 upgraded from low risk. The Gleason grade subgroups 
according to ISUP category with corresponding stage based on RP histology are presented in 
Table 1. Primary Gleason pattern 4 or higher or tertiary pattern 5 was present in 34 patients 
based on RP histology. The demographic information for each group (Table 1) demonstrated that 
serum PSA was higher in those with high D’Amico risk or who were ineligible for active 
surveillance. The remaining 38 patients received radiation based therapy (n =17), androgen 
deprivation therapy for metastatic disease (n =2) or embarking on conservative management 
(active surveillance, watchful waiting; n = 12), while 7 were lost to follow up. 
Unsupervised multivariate statistical analysis  
The SP samples were analysed with 1H NMR spectroscopy. One-dimensional NOESY spectra 
were measured, aligned, and data reduced to 0.01 buckets. For initial PCA, buckets 
corresponding to ethanol, resulting from sample preparation, were excluded, as were spectra that 
were outliers due to broad resonances (n=2). PCA yielded a model (Supplementary Table 1 M1) 
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with 6 principal components (PCs), in which samples clustered per the buffer solution used 
(PC1/PC2; Figure 2a-c), with higher glucose levels in samples prepared in HBSS. In higher PCs, 
sample variation was observed due to inter-sample differences of lipids/lipoproteins, 
phosphocholine, choline and citrate, as well as spermine (data not shown), which were unrelated 
to CaP in this analysis.  
The “Add-to-Subtract” method20 was used to remove glucose signals from NMR spectra. 
Following measurement of a “baseline spectrum” (spectrum 1), glucose was added in high 
concentration to the sample in the same NMR tube and a second spectrum was measured 
(spectrum 2). Spectrum 2 was subtracted from spectrum 1 with an appropriate scaling factor to 
remove glucose signals but preserve signals of all other compounds in the resulting difference 
spectrum. The method assumes that introduction of the compound of interest does not change 
sample conditions, preserving sample matrix, line shapes and signal frequencies.  
PCA of the difference spectra (Figure 2d-f, Supplementary Table 1 M2) showed no sample 
grouping due to differences in buffer used (Figure 2d). The predominant drivers of sample 
variation were lipids/lipoproteins (PC1), an inverse relationship between choline and 
phosphocholine as well as citrate. An association with csCaP was suggested by the presence of 
lipids/lipoproteins, although separation between clinical groups was not observed in any PC.  
Given that the inverse relationship observed between phosphocholine and choline is due to PAP-
mediated hydrolysis, a reaction which was not inhibited in these samples26, choline-based 
metabolites (choline, phosphocholine and glycerophosphocholine) were excluded to remove their 
effect of unbalanced regulation on the MVSA. However, PCA (Figure 3, Supplementary Table 1 
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M3) showed no obvious clustering, with most variation due to lipids/lipoproteins, citrate and 
serine (Figure 3a,b). Fructose and spermine were other significant sources of variation in 
PC3/PC4 (Figure 3c,d) 
 
Supervised multivariate statistical analysis  
In the unsupervised PCAs, which determine sources of variation potentially independent of 
underlying biology, no sample clustering into clinical groups was seen, prompting the need for 
supervised MVSA. First, the presence of csCaP according to the D’Amico criteria based on 
biopsy was used as the predictive variable in PLS analysis (Figure 4, Supplementary Table 1 
M4) and demonstrated lipids/lipoproteins to be associated with variation for csCaP, which were 
mostly limited high-risk patients. Furthermore, there was potential subgrouping among the 
D’Amico risk groups (Figure 4b).  
Based on these results and reports that maximal metabolite disturbances are observed in low- and 
intermediate-risk tumours, we analysed with PLS a subgroup of 11 samples correlating to these 
grades confirmed by RP histology only (Figure 5a-c, Supplementary Table 1 M5). The single 
low-risk sample was separated from the intermediate-risk samples due to reduced lactate, 
pyruvate and lipids/lipoproteins and increased citrate, myo-inositol, spermine and fructose 
(Figure 5a,c). Within these low/intermediate-risk samples, separation was seen in accordance 
with primary Gleason pattern 4, associated with higher levels of lipids/lipoproteins, lactate and 
pyruvate as well as lower levels of citrate, spermine and myo-inositol (Figure 5b,c). These 
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relationships were observed when classifiers based on all low/intermediate-risk patients, 
determined by biopsy or RP, were performed (Figure 5d,e; Supplementary Table 1 M6).  When 
benign samples were considered with risk group combinations and Primary Gleason pattern 4 
presence, minimal separation was observed and models were weak/non-predictive 
(Supplementary Figure 1, Supplementary Table 1 M7-M10).  
Analysis of only the samples collected in PBS, unaffected by any external glucose 
(Supplementary Figure 2, Supplementary Table 1 M11-17), showed similar relationships to those 
seen for the full cohort. Specifically, valid models were obtained for separation between low- 
and intermediate-risk samples (M12, Supplementary Figure 2c,d; limited by sample size) and 
low-risk and benign samples (M13, Supplementary Figure 2e,f). Findings were confirmed with 
PCA (M15-17, Supplementary Figure 3) and driven by lactate levels (Supplementary Figure 4). 
The presence of the TMPRSS2:ERG fusion gene, detected in the epithelial cell fraction of SP, 
used as Y variable was weakly but non-predictively associated with lipid/macromolecule 
resonances (Supplementary Figure 5, Supplementary Table 1 M18).  
Targeted metabolite profiling 
SP metabolite quantification with subsequent logistic regression showed that citrate or myo-
inositol were not significant predictors of CaP status (Table 2). Significant metabolites for CaP 
status (choline, leucine) and csCaP (leucine, valine) did not significantly improve diagnosis 
compared with serum PSA metabolite predictability. 
Discussion 
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In this paper, we present the largest validation study of SP-based metabolite prediction of CaP 
using high resolution NMR spectroscopy, having analysed SP metabolite profiles from 151 men 
being investigated for CaP. Undue influence of exogenous glucose contained in the HBSS buffer 
used for RNA analyses was successfully excluded by applying Add-to-Subtract and revealed 
inherent variation due to enzyme-dependent changes in choline-based metabolites. SP 
metabolites best predicted low- and intermediate-risk PCa with differences observed between 
these groups and benign and high-risk samples. Metabolites previously reported to determine 
CaP, such as citrate, spermine and myo-inositol, showed minimal predictive ability in this 
clinically applicable cohort. These findings were confirmed with targeted metabolite 
quantification.  
Well described prostatic metabolite changes due to CaP, specifically reduced citrate and 
polyamines (e.g. myo-inositol, spermine) and increased intracellular lactate, choline and 
creatine12, were not predictive in this study due to underlying the following clinical and 
biological factors: Clinically, the study population presented here contains patients suspected of 
harboring CaP, encountered in daily urological practice (Table 1). In earlier reports where SP 
metabolites significantly improved CaP detection, CaP-positive samples were compared with 
healthy controls or men unlikely to have CaP, suggested by marked discrepancies in serum PSA 
between groups. Our population contained heterogeneous disease states, inclusive of all tumour 
grades with predominance toward high-risk CaP. While group separation was observed between 
CaP risk groups (Figure 5, Supplementary Figures 2,3), we could not truly exclude CaP in 
patients with a negative biopsy due to limitations in biopsy-based CaP detection and known 
metabolic changes in early tumorigenesis, which may lead to confounding overlap between 
groups and invalid statistical models. To exclude uncertainty among the control group, a 
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subanalysis of the presence or absence of Gleason pattern 4 on RP histology showed overlap of 
groups (M10, Supplementary Figure 1g,h), likely owing to reduced metabolite influence in 
poorly differentiated tumours. Similarly, limitations of biopsy-based risk stratification given 
known upstaging at RP in up to 40% of patients may confound the accuracy of risk subgroup 
analyses27. When analyses based only on RP-based diagnosis were expanded to include biopsy-
based diagnosis to increase sample size, sample grouping was less obvious despite similar 
metabolite patterns being observed in the loadings plot (Figure 5). Thus, a larger low-
/intermediate-risk RP cohort would be expected to accurately “up-classify” (upstage) low-risk 
samples with metabolite patterns similar to intermediate-/high-risk samples, as shown 
elsewhere28. 
Biologically, Gene expression and metabolite alterations occur early in tumorigenesis and are 
more pronounced in lower grade (Gleason≤7) compared with higher grade (Gleason≥8) 
tumours28, supported by our analysis of low- and intermediate-risk patients (Figure 5, 
Supplementary Figures 2,3). In addition to direct metabolic changes, the inverse relationship 
between lactate and fructose resulting in group separation between low- and intermediate-risk 
and benign samples may indicate disturbed SP homeostasis of anions (zinc) or enzymes (PSA, 
PAP) known to improve sperm function29, resulting in impaired sperm glycolysis. Indeed, poor 
discrimination of metabolite profiles from high-risk tumours was demonstrated here and in other 
studies, likely due to accumulated genetic alterations with disease progression28,30.  Thus, 
patients with lower grade tumours may be amenable to SP-mediated in vitro or magnetic 
resonance spectroscopic imaging (MRSI)-mediated in vivo assessment or monitoring as a 
potential substitute for repeat biopsy in active surveillance28,31. 
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Altered metabolite homeostasis correlates with increased fatty acid synthesis, due to or in 
association with TMPRSS2-ERG fusion gene translocation associated with aggressive CaP, may 
account for the overwhelming influence of lipids/lipoproteins in high-risk patients in this study, 
similar to that reported by others32. Higher grade tumours overexpress the oncogene MYC, 
which is associated with dysregulated lipid metabolism33 and display altered cholesterol 
metabolism to increase energy storage30 . Upregulated lipid subclasses have been described 
between normal, localized and metastatic prostatic cells, with choline kinase α implicated in de 
novo lipogenesis in aggressive metastatic cells34. Systemically, lipid and energy metabolites in 
serum have been strongly associated with aggressive CaP35 and may improve CaP detection.  
This study was an opportunistic analysis of SP samples collected initially for cytology and 
subsequently epithelial cell RNA analyses. The exogenous glucose contained in the HBSS 
required significant correction using Add-to-Subtract, which did not introduce further influence 
into the MVSA. Subsequently, the uninhibited changes in choline-based metabolites showed 
significant influence in the preliminary MVSA. These metabolite peaks were excluded because 
PAP-catalysed hydrolysis of phosphocholine to choline is a rapid, endogenous reaction to 
enhance spermatozoal function and protection26. Variations in time from sample production to 
processing, despite most being done within 2 hours, are likely to cause significant variation 
among these metabolites independent of underlying CaP due to the unknown degree of reaction 
completion. Given the postulated role of choline in tumour progression, as indicated by elevated 
in vivo levels, reliable quantification of choline-based metabolites in SP is desired. Thus, a 
sample collection/storage protocol should be implemented that limits the PAP reaction to 2-3% 
progression, such as our recommendation that ejaculate samples be collected in a sterile urine jar 
containing 5 mM tartrate in 20 ml PBS solution cooled to 277 K26. While malignant prostatic 
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metabolite contribution to SP, considering concurrent contributions from multiple organs and 
resulting proteolysis, may intuitively be minimal or diluted, our findings are similar to those seen 
in tissue extracts and in vivo28,30, likely to be enhanced by spectral acquisition at 900 MHz. 
While prostatitis is known to reduce prostatic citrate and zinc content12 and potentially affect 
MVSA, this influence in the current study would be minimal due to the focus on RP-based and 
malignant pathology, as well as only being confirmed histologically for 2 patients. 
In conclusion, metabolomics of seminal plasma in vitro may assist diagnosis and monitoring of 
either low or intermediate grade prostate cancer. Lipids/lipoproteins dominated spectra of high 
grade samples with less contributions from other metabolites. As a validation study, we were 
unable to replicate previous performance of SP-based metabolite prediction of CaP in 151 men 
being investigated for CaP. Dedicated metabolomics protocols ideally in serial collections may 
maximize information recovery. The value of metabolomics analysis of SP for CaP currently 
appears to be in active surveillance of low- or intermediate-grade tumours suspicious of under-
staging, in which in vivo correlation with MRSI and monitoring in vitro with SP or in vivo with 
MRSI may further clinical practice.  
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Figure Legends 
Figure 1 Sections of 1D NOESY spectra from seminal plasma (SP) measured at 900 MHz. Panel 
A – 1D NOESY spectrum of SP collected in HBSS, with additional peaks due to exogenous 
glucose present. Panel B – 1D NOESY spectrum of SP collected in PBS.   Metabolite 
abbreviations; Ala = alanine, Arg = arginine, Asn = asparagine, Cho = choline, Cit = citrate, 
DFTMP = 1,1-difluoro-1-trimethylsilanyl methylphosphonic acid, DSS = 4,4-dimethyl-4-
silapentane-1-sulfonic acid, Fru = fructose, Gln = glutamine, Gluc = glucose, Glu = glutamate, 
Ile = isoleucine, Lac = lactate, Leu = leucine, Lys = lysine, PCho = phosphocholine, Pyr = 
pyruvate, Spe = spermine, Val = valine. 
Figure 2 Principal Components Analysis of seminal plasma NMR spectra from men being 
investigated for prostate cancer (n = 151), prepared with different buffer solutions (Hanks 
Balanced Salt Solution: filled square, phosphate buffered saline: empty square). Panels a-c: 
Initial sample clustering is observed due to the difference in buffer solutions and resulting 
sample glucose content (principal component 1) and inter-sample differences in metabolite 
(citrate, choline, lipids/lipoproteins and phosphocholine) variation (principal component 2). 
Panels d-f: After Add-to-Subtract elimination of glucose, the previously observed effects of 
different buffer solutions are no longer apparent (panel a). No clustering was present according 
to CaP status (blue squares = benign; red triangles = CaP). Panels a, b, d, e: scores plots; panels 
c, f: loadings plots. Metabolite abbreviations: Cho = choline; Cit = citrate; Gluc = glucose; Lip = 
lipids/lipoproteins ; PCho = phosphorylcholine.  
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Figure 3 Principal Components Analysis after exclusion of choline containing metabolites 
demonstrated that lipids/lipoproteins, citrate and serine were influential metabolites (panels a, b) 
as well as fructose and spermine (panels c, d). No clustering was present according to CaP status 
(blue squares = benign; red triangles = CaP). Panels a, c: scores plots; panels b, d: loadings plots. 
Metabolite abbreviations: Cit = citrate; Fru = fructose; Lip = lipids/lipoproteins Ser = serine; Spe 
= spermine.  
 
Figure 4 Supervised, partial least squares analysis of seminal plasma NMR spectra in predicting 
csCaP (according to D’Amico criteria) following Add-to-Subtract. Minimal separation is seen 
according to csCaP (blue squares = benign, red triangles = csCaP; panel a). When coloured 
according to risk subgroups (blue squares = benign; green dots = low risk; yellow diamonds = 
intermediate risk; red triangles = high risk/cancer present; panel b), potential intragroup 
clustering was seen due to pyruvate, serine and lipids/lipoproteins (high/intermediate risk) and 
TMAO (low risk).  Panels a, b: scores plots; panel c: loadings plot. Metabolite abbreviations: Lip 
= lipids/lipoproteins; Pyr = pyruvate; Ser = serine; TMAO = trimethylamine N-oxide.  
 
Figure 5 Supervised, partial least squares analysis of seminal plasma NMR spectra in predicting 
CaP risk (according to D’Amico criteria) following Add-to-Subtract. Separation between low- 
(green dots) and intermediate- (yellow diamonds) risk patients based on RP histology due to 
elevated lactate, lipids/lipoproteins and pyruvate and reduced citrate, fructose, myo-inositol and 
spermine in intermediate-risk samples (panels a,c). These relationships were observed when 
expanded to all low and intermediate risk patients (panels d, e). Discrimination within the 
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low/intermediate group was observed due to primary Gleason pattern 4 (filled square = present; 
empty square = absent) and higher lipids/lipoproteins, lactate and pyruvate as well as reduced 
citrate, myo-inositol and spermine (panels b,c). Panels a, b, d: scores plots; panels c, e: loadings 
plots. Metabolite abbreviations: Cit = citrate; Fru = fructose; Lac = lactate; Lip = 
lipids/lipoproteins; Myo = myo-inositol; Pyr = pyruvate; Spe = spermine.  
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Table 
  Age (years) Serum PSA 
(ng/mL) 
Pathological stage (n) 
pT2 pT3a pT3b 
Biopsy n = 151      
Overall  61 (55 – 66)  6.5 (4.3 – 9.2)     
CaP status Positive (n = 98) 60.5 (55 – 65) 6.4 (4.5 – 11)    
Negative (n = 53) 62 (55.75 – 
68.25)NS  
6.5 (3.6 – 7.9)NS    
csCaP 
status 
Present (n = 82) 61 (55 – 66) 6.75 (4.5 – 11.9)    
Absent (n = 69) 61 (55 – 67)NS 6.0 (3.6 – 8.1)*    
RP n = 60      
Overall  57 (54 – 64)   6.15 (4.1 – 9.1)     
ISUP 
Group 
1 (n = 2) 56 (54 – 57) 6.5 (4 – 9 )  2   
2 (n = 30) 57.5 (53 – 64) 5.5 (4 – 7) 26 3 1 
3 (n = 20) 57 (55 – 61) 7.3 (5 – 12) 15 5  
4 (n = 1) 55 19 1   
5 (n = 7) 60 (55 – 68) 10 (6 – 12) 3 1 3 
Primary/ 
tertiary 
pattern 
≥ 4 (n = 33) 57 (55 – 64) 7.3 (5 – 12) 23 7 3 
3 (n = 27) 57 (51 – 63)NS 5.4 (4 – 7)** 25 2 1 
 
Table 1 Demographic information for patients based on biopsy and radical prostatectomy (RP) 
histology. Median and interquartile range are shown for age and serum PSA. All comparisons 
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were made using the Mann-Whitney U-test (two-tailed). * p < 0.05; ** p < 0.01; NS, not 
significant. 
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 Metabolite Mean (± Std. Error) (mM) 
Logistic Regression (log base 10) ROC analysis 
P-value Coefficient Std. Error AUC 
Std. 
Error 
 
Pr
o
st
at
e 
ca
n
ce
r 
st
a
tu
s 
alanine 0.1734 (0.0208) 0.7998 0.5211 2.0552 0.555 0.0498 
choline 1.3326 (0.1392) 0.0291 2.0211 0.9263 0.556 0.0495 
citrate 2.9243 (0.2643) 0.1490 -1.2433 0.8616 0.542 0.0490 
creatine 0.1156 (0.0114) 0.8786 -0.1850 1.2113 0.565 0.0492 
fructose 1.0591 (0.1004) 0.9631 -0.0413 0.8938 0.603 0.0510 
glucose 3.2694 (0.2118) 0.9144 -0.0262 0.2439 0.629 0.0487 
glutamine 0.5802 (0.0604) 0.8559 -0.3076 1.6943 0.541 0.0509 
glycerophosphocholine 0.2259 (0.0236) 0.0951 -1.0546 0.6318 0.603 0.0485 
lactate 0.8520 (0.0645) 0.5879 -0.5962 1.1003 0.579 0.0484 
leucine 0.4067 (0.0416) 0.0008 -12.3505 3.6772 0.572 0.0499 
myo-inositol 0.3251 (0.0238) 0.9287 -0.1095 1.2238 0.592 0.0472 
phosphocholine 0.1810 (0.0459) 0.1042 0.6905 0.4250 0.543 0.0499 
serum PSA 8.0867 (0.6075)* 0.0601 1.5605 0.8299 0.593 0.0472 
pyruvate 0.3709 (0.0373) 0.9736 -0.0286 0.8672 0.546 0.0493 
uridine 0.1793 (0.0167) 0.7146 0.1528 0.4180 0.568 0.0495 
valine 0.3206 (0.0392) 0.0013 1.4923 1.6868 0.534 0.0503 
 
C
lin
ic
a
lly
 
sig
n
ifi
ca
n
t p
ro
st
a
te
 
ca
n
ce
r 
alanine 0.1734 (0.0208) 0.1629 -2.2913 1.6421 0.592 0.0466 
choline 1.3326 (0.1392) 0.1595 1.1536 0.8200 0.584 0.0467 
citrate 2.9243 (0.2643) 0.1147 -1.4430 0.9147 0.580 0.0466 
creatine 0.1156 (0.0114) 0.8808 -0.1703 1.1364 0.603 0.0465 
fructose 1.0591 (0.1004) 0.5227 -0.5368 0.8397 0.611 0.0470 
glucose 3.2694 (0.2118) 0.3728 0.1970 0.2211 0.584 0.0475 
glutamine 0.5802 (0.0604) 0.4141 1.1168 1.3674 0.572 0.0473 
glycerophosphocholine 0.2259 (0.0236) 0.4243 -0.4494 0.5624 0.599 0.0463 
lactate 0.8520 (0.0645) 0.8719 -0.1501 0.9313 0.582 0.0467 
leucine 0.4067 (0.0416) 0.0025 -9.2502 3.0562 0.597 0.0466 
myo-inositol 0.3251 (0.0238) 0.4242 0.9335 1.1681 0.609 0.0459 
phosphocholine 0.1810 (0.0459) 0.2600 0.4343 0.3856 0.506 0.0477 
serum PSA 8.0867 (0.6075)* 0.0228 1.7942 0.7880 0.617 0.0456 
pyruvate 0.3709 (0.0373) 0.6820 -0.3337 0.8146 0.569 0.0472 
uridine 0.1793 (0.0167) 0.2795 0.4318 0.3993 0.568 0.0473 
valine 0.3206 (0.0392) 0.0030 9.7952 3.2968 0.571 0.0471 
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Table 2: Logistic regression weightings following targeted metabolite quantification using 
Chenomx, similar to that reported by18. Among 151 patients, CaP status (positive 98, negative 
53) and D’Amico risk (high = 82, low = 69) were used as dependent variables (Enter, p enter 
0.05, p exclude >0.1). *serum PSA determined using immunoassay, units ng/mL. 
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